-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Genmab, Raises Price Target to $54

Benzinga·10/05/2026 13:01:02
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $45 to $54.